LTQ Orbitrap Velos Mass Spectrometer with ETD

带 ETD 的 LTQ Orbitrap Velos 质谱仪

• 批准号: 8246887
• 负责人: Marc J Glucksman
• 金额: $ 60万
• 依托单位: ROSALIND FRANKLIN UNIV OF MEDICINE & SCI
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-04-15 至 2013-04-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8246887
• 关键词: Area; Basic Science; Biomedical Research; Cellular biology; Chicago; Cocaine Dependence; Communicable Diseases; Core Facility; Coupled; Discipline; Dissociation; Electron Transport; Equipment; Faculty; Funding; Gap Junctions; Harvest; Hour; Illinois; Individual; Institutes; Institution; Manufacturer Name; Marketing; Mass Spectrum Analysis; Medicine; Methods; Muscle Development; National Center for Research Resources; Neurons; Nuclear; Plants; Proteins; Proteome; Proteomics; Pulmonary Valve Insufficiency; Request for Proposals; Research; Research Personnel; Resolution; Science; Seeds; Signal Transduction; Staging; Structure; Technology; United States National Institutes of Health; Universities; Update; base; design; instrument; instrumentation; mass spectrometer; medical schools; meetings; programs; structural biology; tool

DESCRIPTION (provided by applicant): The Midwest Proteome Center was created at the Rosalind Franklin University of Medicine and Science (RFUMS)/Chicago Medical School in 2003 to bolster the proteomics initiatives centered upon mass spectrometry. As a targeted technology to update our research capabilities in structural biology and proteomics, and to insure state-of-the-art instrumentation for a major expansion already underway, RFUMS has targeted the acquisition of a ThermoFisher LTQ Orbitrap Velos with Electron Transfer Dissociation (ETD) mass spectrometer. With the exception of FT/ICR instruments, the Velos has the highest mass accuracy, resolution and dynamic range on the market, coupled with multiple fragmentation methods. Mass spectrometry is now a routine structure analysis and identification tool with the Midwest Proteome Center the nexus of many biomedical research initiatives identified by the University. This proposal requests the LTQ Orbitrap Velos ETD mass spectrometer to assist fifteen major users, seven of which have recently received New/Early stage NIH funding, in all five of the basic science research departments, funded by ten Institutes of the NIH requiring protein characterization, identification and proteomics. Currently, our NIH supported users exceed the capacity and specifications of our much older equipment, some about which are to lose manufacturer support; the fundamental reason for this request. While several universities 1.5 hours south in Chicago (the Chicago Biomedical Consortium comprising U. of Chicago, Northwestern U., and U. of Illinois in Chicago only) have older machines with an instrument similar to this request, in Core Facilities or within individual labs, researchers at RFUMS have no access to this crucial technology. As detailed in the NIH project descriptions, the rapidly expanding demands of our NIH supported researchers, and newly hired faculty, require the increased mass accuracy, resolution, throughput and capabilities afforded by the Orbitrap Velos ETD to assist studies of infectious diseases, cocaine addiction, muscle development, pulmonary insufficiency, neural cell signaling, nuclear cell biology and structural biology, with adjunct proteomic approaches to many of these areas. The Midwest Proteome Center core facility obtained a QSTAR XL (QqTOF) in 2003 under the auspices of the S10 program, and provided substantial "bang for the buck" with supplemented funds from the institution. The seed planted by the NCRR 8 years ago yielded a bountiful harvest with respect to expansion of the instrument repertoire, increased user base, faculty hires obtaining New/Early Stage NIH funding and our established investigators availing themselves of "cutting edge" technology. The wide breadth of disciplines supported by this submission is at the crossroads of the NIH Roadmap. The proposed LTQ Orbitrap Velos ETD is designed to meet the diverse and realized research needs of users in virtually every basic science department and research center at RFUMS. PUBLIC HEALTH RELEVANCE: This submission will augment sponsored research by providing mass spectrometry support in diverse areas funded by ten Institutes of the NIH. Fifteen major users have been enrolled, half of them New/Early Stage Investigators with their first grants. Crucial areas of health research to be explored are: infectious diseases, cocaine addiction, muscle development, pulmonary insufficiency, cell signaling in the brain, nuclear cell biology and membrane structural biology.

描述（由申请人提供）：中西部蛋白质组中心于 2003 年在罗莎琳德·富兰克林医学与科学大学 (RFUMS)/芝加哥医学院创建，旨在支持以质谱分析为中心的蛋白质组学计划。作为一项有针对性的技术，旨在更新我们在结构生物学和蛋白质组学方面的研究能力，并确保为正在进行的重大扩展提供最先进的仪器，RFUMS 的目标是收购配备电子转移解离 (ETD) 质谱仪的 ThermoFisher LTQ Orbitrap Velos。除 FT/ICR 仪器外，Velos 具有市场上最高的质量精度、分辨率和动态范围，以及多种碎片方法。质谱现在是中西部蛋白质组中心的常规结构分析和识别工具，该中心是该大学确定的许多生物医学研究计划的纽带。 该提案要求 LTQ Orbitrap Velos ETD 质谱仪协助 15 个主要用户，其中 7 个最近获得了 NIH 新/早期阶段的资助，涉及所有 5 个基础科学研究部门，由 NIH 的 10 个研究所资助，需要蛋白质表征、鉴定和蛋白质组学。目前，我们 NIH 支持的用户超出了我们老旧设备的容量和规格，其中一些设备将失去制造商的支持；提出这一要求的根本原因。虽然位于芝加哥以南 1.5 小时车程的几所大学（仅由芝加哥大学、西北大学和伊利诺伊大学组成的芝加哥生物医学联盟）在核心设施或个别实验室内拥有配备与此要求类似的仪器的旧机器，但 RFUMS 的研究人员无法获得这项关键技术。正如 NIH 项目描述中所详述的，我们 NIH 支持的研究人员和新聘用的教师的需求迅速扩大，需要 Orbitrap Velos ETD 提供更高的质量精度、分辨率、通量和功能，以协助传染病、可卡因成瘾、肌肉发育、肺功能不全、神经细胞信号传导、核细胞生物学和结构生物学的研究，并辅以蛋白质组学 其中许多领域的方法。 中西部蛋白质组中心核心设施于 2003 年在 S10 计划的支持下获得了 QSTAR XL (QqTOF)，并通过该机构的补充资金提供了大量“物有所值”的服务。 NCRR 八年前播下的种子在仪器库扩展、用户基础增加、教师聘用获得新/早期 NIH 资金以及我们现有的研究人员利用“尖端”技术等方面取得了丰硕的成果。本次提交所支持的广泛学科正处于 NIH 路线图的十字路口。拟议的 LTQ Orbitrap Velos ETD 旨在满足 RFUMS 几乎每个基础科学部门和研究中心用户的多样化和现实的研究需求。 公共卫生相关性：本提交内容将通过在 NIH 十个研究所资助的不同领域提供质谱支持来增强赞助研究。已注册 15 个主要用户，其中一半是获得第一笔资助的新/早期研究人员。需要探索的健康研究的关键领域是：传染病、可卡因成瘾、肌肉发育、肺功能不全、大脑细胞信号传导、核细胞生物学和膜结构生物学。

项目成果

Identification and characterization of Aβ peptide interactors in Alzheimer's disease by structural approaches.

• DOI: 10.3389/fnagi.2014.00265
• 发表时间: 2014
• 期刊: Frontiers in aging neuroscience
• 影响因子: 4.8
• 作者: Philibert KD;Marr RA;Norstrom EM;Glucksman MJ
• 通讯作者: Glucksman MJ

Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 Batten disease.

• DOI: 10.1038/s41591-020-0986-1
• 发表时间: 2020-09
• 期刊: Nature medicine
• 影响因子: 82.9
• 作者: Centa JL;Jodelka FM;Hinrich AJ;Johnson TB;Ochaba J;Jackson M;Duelli DM;Weimer JM;Rigo F;Hastings ML
• 通讯作者: Hastings ML

Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis.

• DOI: 10.1073/pnas.2114886119
• 发表时间: 2022-01-18
• 期刊: Proceedings of the National Academy of Sciences of the United States of America
• 影响因子: 11.1
• 作者: Michaels WE;Pena-Rasgado C;Kotaria R;Bridges RJ;Hastings ML
• 通讯作者: Hastings ML

Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.

• DOI: 10.18632/oncotarget.9835
• 发表时间: 2016-09-13
• 期刊: Oncotarget
• 作者: Goswami S;Sharma-Walia N
• 通讯作者: Sharma-Walia N

EP24.15 as a Potential Regulator of Kisspeptin Within the Neuroendocrine Hypothalamus.

EP24.15 作为神经内分泌下丘脑内 Kisspeptin 的潜在调节剂。

• DOI: 10.1210/en.2015-1580
• 发表时间: 2016
• 期刊: Endocrinology
• 影响因子: 4.8
• 作者: Woitowich,NicoleC;Philibert,KeithD;Leitermann,RandyJ;Wungjiranirun,Manida;Urban,JaniceH;Glucksman,MarcJ
• 通讯作者: Glucksman,MarcJ